Edwards Lifesciences Corp (EW)vsHeart Test Laboratories Inc. Common Stock (HSCS)
EW
Edwards Lifesciences Corp
$91.78
+1.06%
HEALTHCARE · Cap: $49.92B
HSCS
Heart Test Laboratories Inc. Common Stock
$3.37
+2.74%
HEALTHCARE · Cap: $15.36M
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 144109216% more annual revenue ($6.51B vs $4,519). EW leads profitability with a 15.4% profit margin vs 0.0%. EW earns a higher WallStSmart Score of 55/100 (C).
EW
Buy55
out of 100
Grade: C
HSCS
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$91.78
$159.67 discount
Intrinsic value data unavailable for HSCS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bull Case : HSCS
The strongest argument for HSCS centers on Debt/Equity. Revenue growth of 10.5% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.5x leaves little room for execution misses.
Bear Case : HSCS
The primary concerns for HSCS are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
EW profiles as a mature stock while HSCS is a value play — different risk/reward profiles.
HSCS carries more volatility with a beta of 1.77 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 19/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Heart Test Laboratories Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company is headquartered in Southlake, Texas.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?